title: Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
abstract: BACKGROUND
  The combined oral contraceptive Yasmin (drospirenone 3 mg plus ethinylestradiol 30 microg [DRSP 3 mg/EE 30 microg]) has been shown to be a well tolerated and effective combination that provides high contraceptive reliability and good cycle control. Furthermore, DRSP 3 mg/EE 30 microg has been shown to have a positive effect on premenstrual symptoms and well-being/health-related quality of life, and to improve the skin condition of women with acne. To date, however, there have been relatively few studies that have compared the effects of DRSP 3 mg/EE 30 microg on the general well-being of women with those of other oral contraceptives.
  
  
  OBJECTIVE
  To compare the impact of DRSP 3 mg/EE 30 microg with that of levonorgestrel 150 microg/EE 30 microg (LNG 150 microg/EE 30 microg; Microgynon 30) on various parameters associated with well-being in healthy female subjects.
  
  
  METHODS
  This was a randomized, single-blind, parallel-group, multicentre study conducted using 21/7-day regimens of DRSP 3 mg/EE 30 microg and LNG 150 microg/EE 30 microg over seven cycles. Efficacy parameters included: changes in Menstrual Distress Questionnaire (MDQ) normative T scores; the proportion of subjects with acne; and menstrual symptoms. Cycle control and subjective well-being parameters were also assessed.
  
  
  RESULTS
  Treatment with DRSP 3 mg/EE 30 microg had similar beneficial effects on symptoms of water retention and impaired concentration to LNG 150 microg/EE 30 microg, but was significantly better in alleviating negative affect symptoms during the menstrual phase (median difference in MDQ T score -3; p = 0.027; Wilcoxon rank sum test). The proportion of subjects with acne decreased from approximately 55% to approximately 45% in the DRSP 3 mg/EE 30 microg group, but remained static at approximately 60% in the LNG 150 microg/EE 30 microg group. Somatic and psychological symptoms occurred at the greatest intensity and for most subjects during the menstrual phase of the cycle in both groups.
  
  
  CONCLUSIONS
  Both drugs had similar cycle control parameters with a tendency towards reduced bleeding with continued use. More subjects in the DRSP 3 mg/EE 30 microg group reported improved physical well-being (60% vs 46%; p = 0.035; chi-squared [chi2] test). Emotional well-being was reported improved in 61% and 51% of DRSP 3 mg/EE 30 microg and LNG 150 microg/EE 30 microg users, respectively (p = 0.1190; chi2 test). Adverse events were typical of oral contraceptive use and did not give rise to any safety concerns. Both products had similar beneficial effects on symptoms of water retention and impaired concentration, but DRSP 3 mg/EE 30 microg was significantly better in alleviating negative affect symptoms during the menstrual phase. The proportion of subjects with acne decreased in the DRSP 3 mg/EE 30 microg group but not in the LNG 150 microg/EE 30 microg group. More subjects in the DRSP 3 mg/EE 30 microg group reported improved physical well-being compared with the LNG 150 microg/EE 30 microg group.
authors.affiliation: Connaught Clinical Consulting, Sydney, New South Wales, Australia.
authors.forename: Sue
authors.initials: S
authors.lastname: Kelly
authors.forename: Emyr
authors.initials: E
authors.lastname: Davies
authors.forename: Simon
authors.initials: S
authors.lastname: Fearns
authors.forename: Carol
authors.initials: C
authors.lastname: McKinnon
authors.forename: Rick
authors.initials: R
authors.lastname: Carter
authors.forename: Christoph
authors.initials: C
authors.lastname: Gerlinger
authors.forename: Andrew
authors.initials: A
authors.lastname: Smithers
mesh_terms: D000293:Adolescent; D000328:Adult; D000736:Androstenes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001834:Body Water / Q000187:drug effects; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008597:Menstrual Cycle / Q000187:drug effects; D011788:Quality of Life; D016037:Single-Blind Method; D018709:Statistics, Nonparametric; D055815:Young Adult
chemical_list: D000736:Androstenes; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; C534342:drospirenone and ethinyl estradiol combination; C072593:ethinyl estradiol, levonorgestrel drug combination; D004997:Ethinyl Estradiol; D016912:Levonorgestrel
references.citation: Eur J Contracept Reprod Health Care. 2007 Sep;12(3):203-11
references.pmid: 17763258
references.citation: J Reprod Med. 2003 Feb;48(2):79-85
references.pmid: 12621790
references.citation: Curr Opin Obstet Gynecol. 2008 Oct;20(5):464-9
references.pmid: 18797269
references.citation: Cutis. 2002 Apr;69(4 Suppl):2-15
references.pmid: 12096825
references.citation: Ann N Y Acad Sci. 1995 Jun 12;761:311-35
references.pmid: 7625729
references.citation: Eur J Contracept Reprod Health Care. 2000 Mar;5(1):25-34
references.pmid: 10836660
references.citation: Eur J Contracept Reprod Health Care. 2000 Jun;5(2):124-34
references.pmid: 10943575
references.citation: J Med Assoc Thai. 2006 Oct;89 Suppl 4:S17-22
references.pmid: 17726807
references.citation: Psychosom Med. 1968 Nov-Dec;30(6):853-67
references.pmid: 5749738
references.citation: Contraception. 1995 Oct;52(4):229-35
references.pmid: 8605781
references.citation: J Am Pharm Assoc (Wash). 2001 Nov-Dec;41(6):875-86; quiz 925-6
references.pmid: 11765113
references.citation: Contraception. 1999 Nov;60(5):269-74
references.pmid: 10717778
references.citation: J Reprod Med. 2002 Jan;47(1):14-22
references.pmid: 11838304
references.citation: Cutis. 2004 Aug;74(2):123-30
references.pmid: 15379365
references.citation: Eur J Contracept Reprod Health Care. 2000 Dec;5 Suppl 3:34-40
references.pmid: 11246600
references.citation: Contraception. 1997 Mar;55(3):131-7
references.pmid: 9115000
references.citation: Contraception. 2000 Jul;62(1):29-38
references.pmid: 11024226
references.citation: J Womens Health Gend Based Med. 2001 Jul-Aug;10(6):561-9
references.pmid: 11559453
references.citation: Eur J Contracept Reprod Health Care. 2003 Jun;8(2):87-92
references.pmid: 12836662
references.citation: Am J Obstet Gynecol. 2002 Jun;186(6):1142-9
references.pmid: 12066088
references.citation: Obstet Gynecol. 2000 Feb;95(2):261-6
references.pmid: 10674591
references.citation: Contraception. 2000 Feb;61(2):105-11
references.pmid: 10802275
references.citation: Am J Med. 1995 Jan 16;98(1A):104S-110S
references.pmid: 7825629
references.citation: Am J Obstet Gynecol. 1999 Nov;181(5 Pt 2):39-44
references.pmid: 10561674